enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ENGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $116.61M
- EPS (TTM)
- -$2.07
- Dividend yield
- None
- 52-week range
- 1.40 – 12.25
- Day range
- 1.69 – 1.80
- Volume / Avg
- 556.72K / 1.12M
- Beta
- —
- Shares outstanding
- 67.02M
52-week range
ENGN stock today
Shares of enGene Therapeutics (ENGN) finished lower on Nov 20 at $1.74, a drop of 1.14% or $0.02 per share, versus the S&P 500's 3.70% decline. Trading was light, with 556.72K shares changing hands, about 50% of the average daily volume. At this level, ENGN sits near the bottom of its 52-week range of $1.40 to $12.25: 85.8% below the high, set on Jan 23, 2026 and 24.3% above the low.
ENGN is down 80.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 75.0%. enGene Therapeutics has posted a net loss over the last twelve months (EPS of -$2.07), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About enGene Therapeutics
Company profileenGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Ronald H. W. Cooper
- Headquarters
- Montreal, QC
- Employees
- 81
- Website
- engene.com
Financial highlights
Full financialsenGene Therapeutics reported a net loss of $117.3 million, compared with a loss of $55.1 million a year earlier. Diluted earnings per share came in at $2.29, up from $1.46.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Growth | — | — | — | — |
| Net income | $-117.30M | $-55.14M | $-99.92M | $-24.46M |
| EPS (diluted) | $2.29 | $1.46 | $151.22 | $44.30 |
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$4.29+146.55%
- Strong buy 2
- Buy 4
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q3 2026)
- Sep 8, 2026
- EPS actual vs est.
- $-0.47 vs —
ENGN news
All ENGN newsenGene Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IVVDInvivyd Inc. | 0.4127 | -7.45% | $122.01M | vs ENGN |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs ENGN |
| HUMAHumacyte Inc. | 0.4454 | -17.90% | $123.73M | vs ENGN |
| CMPXCompass Therapeutics Inc. | 0.6882 | +1.43% | $123.94M | vs ENGN |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs ENGN |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs ENGN |
| MOLNMolecular Partners AG ADR | 2.53 | -5.25% | $96.80M | vs ENGN |
| IPHAInnate Pharma S.A. ADS | 0.8634 | -8.14% | $96.44M | vs ENGN |
Indexes, lists and sector
enGene Therapeutics stock FAQ
What is enGene Therapeutics's stock price today?
ENGN last traded at $1.74 as of Nov 20, 4:00 PM EST, down 1.14% on the day. Prices are delayed at least 15 minutes.
Who is enGene Therapeutics's CEO?
Mr. Ronald H. W. Cooper is the chief executive officer of enGene Therapeutics Inc., which has about 81 employees.
What is the ENGN 52-week high?
The 52-week high for ENGN is $12.25 and the 52-week low is $1.40. The stock is currently 85.8% below its high.